Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2025-09-16

Clinical Trial Update: 177Lu-DOTATATE for Recurrent Meningioma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for 177Lu-DOTATATE in recurrent meningioma; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LUTATHERA (Lutetium Lu-177 dotatate)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Recurrent Meningioma | Phase 2 | Status: RECRUITING